Safety and Feasibility of Multipotent Adult Progenitor Cells for Immunomodulation Therapy After Liver Transplantation: A Phase I Study of the MiSOT Study Consortium

Trial Profile

Safety and Feasibility of Multipotent Adult Progenitor Cells for Immunomodulation Therapy After Liver Transplantation: A Phase I Study of the MiSOT Study Consortium

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Allogeneic stem cell therapy Athersys (Primary)
  • Indications Liver transplant rejection
  • Focus Adverse reactions
  • Acronyms MiSOT; MISOT-I
  • Most Recent Events

    • 24 Mar 2017 Status changed from recruiting to discontinued.
    • 18 Feb 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.
    • 16 Apr 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top